#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
Two breweries in the Greater Cincinnati area have filed a lawsuit challenging Ohio’s prohibition on beverages containing THC, arguing that the state’s current regulatory framework unfairly restricts cannabis-infused products while allowing alcohol. The lawsuit highlights a legal and regulatory inconsistency in Ohio’s cannabis framework, where THC beverages remain banned despite the state’s legalization of medical cannabis and hemp-derived products. This legal challenge could potentially reshape how cannabis beverages are regulated and made available in Ohio, similar to regulatory shifts occurring in other states that have permitted such products. If the breweries succeed, clinicians may need to familiarize themselves with THC beverage products as a delivery mechanism their patients could access, requiring knowledge of dosing, onset times, and metabolic differences compared to other cannabis forms. Clinicians should monitor this lawsuit’s progress and Ohio’s evolving cannabis regulations to stay informed about what products their patients may encounter or request. The practical takeaway for clinicians is to remain aware of state-level legal developments affecting cannabis product availability, as regulatory changes can quickly alter the landscape of what patients can legally access and what counseling may be needed.
“What we’re seeing with these lawsuits is the inevitable collision between federal prohibition and state legalization, and patients caught in the middle are the ones paying the price—they can’t access a standardized, measured product that would actually be safer than black market alternatives, and I have to tell them that, which frankly undermines my ability to practice evidence-based medicine.”
? The legal challenge to Ohio’s ban on THC beverages highlights an evolving regulatory landscape that clinicians should monitor, as jurisdictional inconsistencies create confusion for patients regarding product legality and safety standards. While some states permit cannabis-infused beverages with quality controls and labeling requirements, Ohio’s prohibition reflects cautious public health positioning, though such restrictions may paradoxically shift consumption toward less-regulated black market alternatives with unknown dosing and contaminants. Clinicians should recognize that beverage formulations present distinct pharmacokinetic considerations compared to other cannabis delivery methods, with variable onset times and absorption patterns that complicate dosing education and adverse effect prediction. As regulatory frameworks continue shifting across states, providers should remain familiar with their local cannabis laws and be prepared to discuss the potential risks of unregulated products with patients, while advocating for evidence-based standards around dosing, labeling, and potency disclosure that would apply regardless of
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
